Core Viewpoint - Argenx SE (ARGX) shows potential for significant upside, with a mean price target of $748.09 indicating a 25.8% increase from its current price of $594.65 [1] Price Targets and Analyst Consensus - The average of 22 short-term price targets ranges from a low of $620 to a high of $1,100, with a standard deviation of $89.83, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 4.3% increase, while the highest suggests an 85% upside, highlighting the range of analyst expectations [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about ARGX's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.9%, with two estimates moving higher and one lower [12] - ARGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

argenex SE (ARGX) shares rallied 4.4% in the last trading session to close at $606.39. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4% loss over the past four weeks.The stock rallied as optimism grew over the company’s marketed product, Vyvgart Hytrulo (efgartigimod), which is approved for treating adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous inje ...

April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annu ...

Core Viewpoint - The FDA has approved argenx's VYVGART® Hytrulo prefilled syringe for self-injection, providing a new treatment option for adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [1][2][3] Group 1: Product Approval and Features - The VYVGART Hytrulo prefilled syringe allows for a 20-to-30-second subcutaneous injection, which can be administered by patients, caregivers, or healthcare professionals [2][3] - This self-injection option is designed to enhance patient independence and flexibility in treatment administration, allowing patients to choose where and when to receive their treatment [2][3][4] - The approval is supported by studies demonstrating the bioequivalence of the prefilled syringe to the vial formulation, along with successful human factors validation studies [3] Group 2: Patient Impact and Community Response - The new self-injection option is expected to improve convenience and reduce the time required for treatment, thereby enhancing disease management for patients with gMG and CIDP [3][5] - The Myasthenia Gravis Foundation of America and the GBS-CIDP Foundation have expressed support for the approval, highlighting its significance in providing effective treatment options that reduce the need for frequent clinic visits [4][5] Group 3: Company Commitment and Support Programs - argenx is committed to innovating the patient experience by providing individualized, safe, and effective therapies, as evidenced by the introduction of the VYVGART Hytrulo prefilled syringe [6] - The company offers a patient support program, My VYVGART® Path, which includes resources for disease education, access support, and financial assistance for eligible patients [6][7] - argenx aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines, reinforcing its position as a leader in the immunology sector [19]

Core Insights - argenx SE presented 15 abstracts at the 2025 American Academy of Neurology Annual Meeting, showcasing long-term data for VYVGART and VYVGART Hytrulo, demonstrating sustained disease control in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile [1][2][3] Group 1: VYVGART and VYVGART Hytrulo Efficacy - VYVGART and VYVGART Hytrulo show differentiated efficacy and safety profiles, with long-term studies indicating significant quality of life improvements for gMG and CIDP patients [3][5] - ADAPT-NXT data reveal that 75% of gMG patients achieved sustained efficacy, with over 56.5% experiencing minimal symptom expression during the study [7] - ADHERE+ data demonstrate functional improvements in CIDP patients, with significant increases in disability scores and grip strength at week 36 compared to baseline [5][6] Group 2: Ongoing Studies and Pipeline - argenx is conducting label expansion studies for VYVGART in ocular myasthenia gravis (oMG) and seronegative myasthenia gravis (snMG) to reach a broader patient community [2][16] - First-in-human data for ARGX-119, a new clinical candidate targeting neuromuscular junction disorders, show a favorable safety profile, supporting its further development [2][31] - The company aims to address unmet needs in underserved patient communities through its robust neuromuscular pipeline [9][34] Group 3: Commitment to Patient Outcomes - The data presented at AAN reinforce argenx's commitment to the neuromuscular community and solidify VYVGART as a leading biologic for improving patient outcomes [3][4] - The company emphasizes individualized treatment options for gMG patients, showcasing the flexibility of VYVGART dosing schedules [6][7] - Real-world data from the ADHERE Phase 4 study indicate a low rate of CIDP worsening among patients transitioning from IVIg to VYVGART Hytrulo [8]

| Table of Contents | | --- | | UNITED STATES | | SECURITIES AND EXCHANGE COMMISSION | | WASHINGTON, D.C. 20549 FORM 20-F | | (Mark One) | | ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES | | EXCHANGE ACT OF 1934 | | OR | | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE | | ACT OF 1934 | | For the fiscal year ended December 31, 2024 | | OR | | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES | | EXCHANGE ACT OF 1934 | | For the tr ...

argenex SE (ARGX) shares ended the last trading session 4.1% higher at $604.96. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.8% loss over the past four weeks.The stock rallied as optimism grew over the company’s marketed product, Vyvgart Hytrulo (efgartigimod), which is approved for treating adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). T ...

Core Insights - argenx SE is presenting clinical trial and real-world data for VYVGART and VYVGART Hytrulo at the American Academy of Neurology Annual Meeting in April 2025, highlighting their commitment to improving the lives of patients with severe autoimmune diseases [1][2]. Group 1: Product Efficacy and Safety - VYVGART has demonstrated long-term benefits for patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), achieving minimal symptom expression and rapid symptom reduction with a favorable safety profile [2][4]. - The largest safety data set for FcRn blocking shows a consistent and favorable safety profile for both VYVGART and VYVGART Hytrulo, supporting individualized treatment approaches [4][5]. - New data from the ADAPT-NXT study indicates sustained clinical improvements in gMG through various dosing regimens over 126 weeks, reinforcing the long-term safety and efficacy of VYVGART [5]. Group 2: Clinical Presentations and Studies - Presentations at the AAN will include interim results from the ADHERE+ study, which supports the long-term efficacy and safety of VYVGART Hytrulo in CIDP [3][5]. - The Phase 4 open-label trial is investigating the transition from intravenous immunoglobulin (IVIg) to VYVGART Hytrulo, aiming to establish effective and safe treatment protocols [5][7]. - The program will feature multiple oral and poster presentations detailing the design and results of various studies related to VYVGART and its applications in treating gMG and CIDP [3][6]. Group 3: Company Overview and Commitment - argenx is dedicated to advancing immunology through innovative antibody-based medicines, focusing on severe autoimmune diseases and collaborating with leading academic researchers [29]. - The company has developed the first approved neonatal Fc receptor (FcRn) blocker, VYVGART, which is now being evaluated for its potential in multiple serious autoimmune diseases [29][24].

argenx SE (NASDAQ:ARGX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel Derek Archila - Wells Fargo Yaron Werber - TD Cowen Victor Floch - BNP Paribas Rajan Sharma - Goldman Sachs Suzanne v ...